Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 10, 2026, reports a significant regulatory milestone for its RSV vaccine, Arexvy. The filing announces that the regulatory application for Arexvy has been accepted for review by China's Center for Drug Evaluation (CDE) for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on a specific product regulatory update rather than a financial results announcement.
Material Changes and Developments
- Regulatory Acceptance: Arexvy is now under regulatory review in China for adults aged 60+, a market where RSV affects over six million people annually.
- Market Potential: If approved, Arexvy will be the first vaccine available in China for this specific indication and population.
- Clinical Data: The submission is supported by a Phase III trial (NCT06551181) in China where all primary endpoints were met, demonstrating an acceptable safety profile and non-inferiority of the immune response compared to adults outside China.
Guidance, Outlook, and Risks
Outlook: A regulatory decision from the CDE is expected in 2027. Arexvy is already approved in more than 65 countries for adults aged 60+ and in over 60 countries for adults aged 50-59 with increased risk.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ due to risks described in GSK's 2024 Form 20-F and Q4 2025 results. Additionally, the company notes that as with any vaccine, a protective immune response may not be elicited in all vaccinees.
Investor Verification Checklist
- Verify the timeline for the expected 2027 regulatory decision in China.
- Review the full Phase III trial data (NCT06551181) regarding immunogenicity and safety in the Chinese population.
- Assess the competitive landscape for RSV vaccines in China post-approval.
- Confirm the commercialization strategy and pricing assumptions for the Chinese market.
- Monitor subsequent filings for any updates on the CDE review process or potential delays.